1,364 reports of this reaction
3.2% of all Praluent reports
#2 most reported adverse reaction
PRODUCT DOSE OMISSION is the #2 most commonly reported adverse reaction for Praluent, manufactured by Regeneron Pharmaceuticals, Inc.. There are 1,364 FDA adverse event reports linking Praluent to PRODUCT DOSE OMISSION. This represents approximately 3.2% of all 42,517 adverse event reports for this drug.
Patients taking Praluent who experience product dose omission should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PRODUCT DOSE OMISSION is moderately reported among Praluent users, representing a notable but not dominant share of adverse events.
In addition to product dose omission, the following adverse reactions have been reported for Praluent:
The following drugs have also been linked to product dose omission in FDA adverse event reports:
PRODUCT DOSE OMISSION has been reported as an adverse event in 1,364 FDA reports for Praluent. This does not prove causation, but indicates an association observed in post-market surveillance data.
PRODUCT DOSE OMISSION accounts for approximately 3.2% of all adverse event reports for Praluent, making it one of the most commonly reported side effect.
If you experience product dose omission while taking Praluent, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.